个人中心 - 老虎社区

Asher123

IP属地：未知

帖子 · 6帖子 · 6
关注 · 0关注 · 0
粉丝 · 0粉丝 · 0

- Asher123Asher123
  ·2021-07-27
  Ok
  5 of the Fastest-Growing Stocks on the Planet
  Sales for these companies are expected to increase between 270% and 1,100% over the next four or five years.
  5 of the Fastest-Growing Stocks on the Planet
  394 评论
  1
  分享
  举报
- Asher123Asher123
  ·2021-07-27
  Ok
  5 of the Fastest-Growing Stocks on the Planet
  Sales for these companies are expected to increase between 270% and 1,100% over the next four or five years.
  5 of the Fastest-Growing Stocks on the Planet
  493 评论
  点赞
  分享
  举报
- Asher123Asher123
  ·2021-07-13
  Liking this
  10 Companies Are About To Post Blowout 1,000%+ Profit Growth
  S&P 500 investors are waiting for banner profit reports to kick off this week. And some companies' profit gains are likely to be enormous.
  10 Companies Are About To Post Blowout 1,000%+ Profit Growth
  274 评论
  1
  分享
  举报
- Asher123Asher123
  ·2021-07-07
  Interesting
  3 Biotechs to Avoid Like the Plague in July
  Generally speaking, biotech is a pretty innovative industry -- with a few notable bad apples.
  3 Biotechs to Avoid Like the Plague in July
  435 评论
  1
  分享
  举报
- Asher123Asher123
  ·2021-06-28
  Great
  非常抱歉，此主贴已删除
  333 评论
  点赞
  分享
  举报
- Asher123Asher123
  ·2021-06-27
  Wow
  5 Buffett Stocks to Buy Hand Over Fist for the Second Half of 2021
  These growth and value stocks are begging to be bought by investors.
  5 Buffett Stocks to Buy Hand Over Fist for the Second Half of 2021
  314 评论
  2
  分享
  举报

热议股票

{"i18n":{"language":"zh_CN"},"isCurrentUser":false,"userPageInfo":{"id":"3571282373975763","uuid":"3571282373975763","gmtCreate":1608351046879,"gmtModify":1624767630674,"name":"Asher123","pinyin":"asher123","introduction":"","introductionEn":"","signature":"","avatar":"https://static.tigerbbs.com/36d4977f7e84ecc5a126c24c142136ca","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":1,"headSize":11,"tweetSize":6,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":0,"name":"","nameTw":"","represent":"","factor":"","iconColor":"","bgColor":""},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"228c86a078844d74991fff2b7ab2428d-1","templateUuid":"228c86a078844d74991fff2b7ab2428d","name":"投资经理虎","description":"证券账户累计交易金额达到10万美元","bigImgUrl":"https://static.tigerbbs.com/c8dfc27c1ee0e25db1c93e9d0b641101","smallImgUrl":"https://static.tigerbbs.com/f43908c142f8a33c78f5bdf0e2897488","grayImgUrl":"https://static.tigerbbs.com/82165ff19cb8a786e8919f92acee5213","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.07.14","exceedPercentage":"60.16%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101},{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-1","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"出道虎友","description":"加入老虎社区500天","bigImgUrl":"https://static.tigerbbs.com/0e4d0ca1da0456dc7894c946d44bf9ab","smallImgUrl":"https://static.tigerbbs.com/0f2f65e8ce4cfaae8db2bea9b127f58b","grayImgUrl":"https://static.tigerbbs.com/c5948a31b6edf154422335b265235809","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.05.04","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"35ec162348d5460f88c959321e554969-1","templateUuid":"35ec162348d5460f88c959321e554969","name":"精英交易员","description":"证券或期货账户累计交易次数达到30次","bigImgUrl":"https://static.tigerbbs.com/ab0f87127c854ce3191a752d57b46edc","smallImgUrl":"https://static.tigerbbs.com/c9835ce48b8c8743566d344ac7a7ba8c","grayImgUrl":"https://static.tigerbbs.com/76754b53ce7a90019f132c1d2fbc698f","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.04.06","exceedPercentage":"60.82%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"976c19eed35f4cd78f17501c2e99ef37-1","templateUuid":"976c19eed35f4cd78f17501c2e99ef37","name":"博闻投资者","description":"累计交易超过10只正股","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":5,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":5,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"page":1,"watchlist":null,"tweetList":[{"id":803086600,"gmtCreate":1627396597500,"gmtModify":1631892526685,"author":{"id":"3571282373975763","authorId":"3571282373975763","name":"Asher123","avatar":"https://static.tigerbbs.com/36d4977f7e84ecc5a126c24c142136ca","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3571282373975763","authorIdStr":"3571282373975763"},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/803086600","repostId":"2154099201","repostType":4,"repost":{"id":"2154099201","kind":"highlight","pubTimestamp":1627384921,"share":"https://ttm.financial/m/news/2154099201?lang=&edition=full","pubTime":"2021-07-27 19:22","market":"us","language":"en","title":"5 of the Fastest-Growing Stocks on the Planet","url":"https://stock-news.laohu8.com/highlight/detail?id=2154099201","media":"Motley Fool","summary":"Sales for these companies are expected to increase between 270% and 1,100% over the next four or five years.","content":"<p>For over 12 years, growth stocks have been the talk of Wall Street -- and with good reason. Persistently low lending rates have allowed fast-growing companies abundant access to cheap capital that they've been able to use to hire new employees, acquire other businesses, and innovate for the future. With the nation's central bank standing firm on its monetary policy, at least in the near-term, growth stocks should continue to thrive.</p>\n<p>Of course, not all growth stocks are created equally. The following five companies are projected by Wall Street to be some of the fastest-growing stocks on the planet over the next four or five years, assuming analysts' sales projections (per <b>FactSet</b>) come to fruition.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/ccad26103b3c97bbb65d0cad160f21b9\" tg-width=\"700\" tg-height=\"489\" width=\"100%\" height=\"auto\"><span>Image source: Getty Images.</span></p>\n<h2><a href=\"https://laohu8.com/S/SNOW\">Snowflake</a>: Implied five-year sales growth of 819%</h2>\n<p>Among cloud stocks, you'd struggle to find a company with a persistently higher annualized growth rate than <b>Snowflake</b> (NYSE:SNOW). After bringing in $592 million in full-year sales in fiscal 2021, Wall Street is looking for the company to deliver $5.44 billion in annual sales in fiscal 2026.</p>\n<p>What really has Wall Street excited are Snowflake's plain-as-day competitive advantages. Most notably, its cloud data-warehousing solutions are layered atop the most-popular infrastructure storage solutions. Whereas it can be difficult for businesses to share data that's stored on competing cloud service providers, this sharing of information is seamless for Snowflake's customers.</p>\n<p>Snowflake also shunned the subscription-based operating model in favor of a pay-as-you-go model. By charging its clients for the amount of data stored and the number of Snowflake Compute Credits used, the company is making its pricing transparent and potentially more cost-effective for users.</p>\n<p>While there's no question Snowflake is <a href=\"https://laohu8.com/S/AONE.U\">one</a> of the fastest-growing stocks on the planet, where the company's stock should be valued is debatable. Though some premium is merited for such consistently high growth rates, I'm not so sure paying 71 times sales for this year makes sense for a company that's still many years away from profitability. There may not be significant downside here, but I also fail to see how this valuation stretches much further to the upside.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/df219df7b01fbc2aa008c455f28b99e5\" tg-width=\"700\" tg-height=\"466\" width=\"100%\" height=\"auto\"><span>Image source: Getty Images.</span></p>\n<h2>Teladoc Health: Implied five-year sales growth of 416%</h2>\n<p>Healthcare stocks on the leading edge of innovation are a pretty good bet to be among the fastest-growing stocks on the planet through mid-decade. Telehealth services giant <b>Teladoc Health</b> (NYSE:TDOC) is expected to see its annual sales climb from a reported $1.09 billion in 2020 to an estimated $5.62 billion by 2025. That's an increase of 416%, for those of you keeping score at home.</p>\n<p>Even though Teladoc found itself in an ideal scenario in 2020, with the coronavirus pandemic wreaking havoc in the U.S., this was a company growing sales by an annualized average of 74% in the six years leading up to the pandemic. In other words, we're clearly not talking about a one-hit wonder.</p>\n<p>Telemedicine is the future of healthcare in the U.S. and globally. While not all appointments can be conducted virtually, telehealth visits will provide added convenience for patients and make it considerably easier for doctor's to keep tabs on patients with chronic illnesses. This ease-of-use should result in improved patient outcomes, which'll mean less money out of the pockets of insurers.</p>\n<p>Teladoc's rapid growth is also a function of its buyout of applied health signals company Livongo Health in the fourth quarter. Livongo leans on artificial intelligence to send its chronically ill members tips to help them lead healthier lives. It ended the first quarter with 658,000 diabetes members, and the company was already profitable before being bought out by Teladoc. As a combined company, this duo looks unstoppable.</p>\n<p class=\"t-img-caption\"><img src=\"https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F635018%2Fsquare-cash-card-cash-app.jpg&amp;w=700&amp;op=resize\" tg-width=\"700\" tg-height=\"520\" width=\"100%\" height=\"auto\"><span>Image source: Square.</span></p>\n<h2>Square: Implied five-year sales growth of 299%</h2>\n<p>Fintech stock <b>Square</b> (NYSE:SQ) is also projected to be one of the fastest-growing companies on the planet through the midpoint of the decade. Following its sales surge in 2020 to $9.5 billion, Wall Street's consensus for 2025 is that it'll bring in $37.86 billion. That's a hair shy of a quadrupling in sales in five years.</p>\n<p>Square's most foundational growth driver, its seller ecosystem, will continue to point the needle higher. The amount of gross payment volume (GPV) traversing its network grew by an annualized average of 49% in the seven years leading up to the pandemic, but tailed off considerably in 2020 as merchants closed up shop due to the pandemic. With the U.S. economy reopening, Square looks to be on track for strong double-digit GPV growth this year.</p>\n<p>However, the company's key growth driver is digital peer-to-peer platform Cash App. Cash App's monthly active user count more than quintupled since the end of 2017 to 36 million, and it's been a consistently more popular download than <b><a href=\"https://laohu8.com/S/PYPL\">PayPal</a></b>'s Venmo.&nbsp; All told, Cash App allows Square to generate revenue from bank transfers, merchant purchases, and investments, which includes <b>Bitcoin</b>&nbsp;exchange and trading.</p>\n<p>As of the end of 2020, the typical Cash App user was generating $41 in gross profit for Square, compared to less than $5 to acquire each new monthly active user. That's a heck of a trade-off that should make Square's shareholders very happy.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/75c8c7cdfeae935529dbccbf6b0c507c\" tg-width=\"700\" tg-height=\"490\" width=\"100%\" height=\"auto\"><span>Image source: Getty Images.</span></p>\n<h2>Jushi Holdings: Implied four-year sales growth of 1,100%</h2>\n<p>The U.S. cannabis industry is home to a number of companies that'll deliver triple-digit sales growth over the next four or five years. But marijuana stock <b>Jushi Holdings</b> (OTC:JUSHF) might have them all beat, with sales growth expected to hit 1,100% by 2024 ($81 million in 2020 to $972 million in 2024).</p>\n<p>Compared to other multistate operators, Jushi is a tiny tot. It has 20 operational dispensaries at the moment, with 13 of those retail locations in Pennsylvania. The real key to Jushi's strategy is targeting markets that offer some level of competitive protection. That's why it's chosen to focus on Pennsylvania, Illinois, and Virginia.</p>\n<p>While all three of these markets offer billion-dollar annual sales potential -- Illinois surpassed $1 billion in weed sales for the first time in 2020 -- the real lure is that they limit how many retail licenses are issued in total, as well as to individual businesses. Pennsylvania and Illinois have preset caps in place, whereas Virginia assigns licenses based on jurisdiction. This effectively limits Jushi's competition and ensures it'll be able to build up its brand and grab a loyal following.</p>\n<p>Investors should also note that, despite its relatively small market cap, Jushi isn't afraid to go shopping. In January, the company acquired two dispensaries in California, the largest weed market in the world by annual sales.&nbsp; It also bought its way into Nevada in April.&nbsp; The Silver State is projected to lead the country in cannabis spending per capita by mid-decade. In other words, smart planning by management has Jushi set up for some serious growth.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/2bd808070a9dde55f37210b59edc2e23\" tg-width=\"700\" tg-height=\"393\" width=\"100%\" height=\"auto\"><span>A Tesla Model S plugged in for charging. Image source: Tesla.</span></p>\n<h2>Tesla Motors: Implied five-year sales growth of 270%</h2>\n<p>A final company most investors know well that has supercharged growth potential over the next five years is electric vehicle (EV) manufacturer <b>Tesla Motors</b> (NASDAQ:TSLA). Tesla brought in $31.5 billion in full-year sales in 2020, but Wall Street's consensus has the company pegged for $116.64 billion in sales by 2025.</p>\n<p>Tesla is a clear and obvious beneficiary of the U.S. and most developed countries wanting to pursue cleaner energy solutions in order to reduce long-term carbon dioxide emissions. It's the first automaker in more than five decades to successfully build itself from the ground up to mass production, and it offers definitive first-mover advantages in the United States.</p>\n<p>In particular, Tesla Motors' battery technology remains unsurpassed, at least for the time being. The company's batteries have better range, more power, and higher capacity than the competition. Considering that cash is no longer a concern, the company has more than enough capital to continue constructing new Gigafactories to assemble its vehicles and produce batteries.</p>\n<p>But like Snowflake, valuation is a serious concern. You'd think a company with a $620 billion market cap, as of this past weekend, would be able to generate a profit from the products or services it sells. That's not the case with Tesla. Its adjusted profits have always come from selling renewable energy credits to other automakers or selling its digital assets (Bitcoin) for a profit. Based solely on its operating performance, Tesla still isn't making money. That makes its existing valuation dicey, at best.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>5 of the Fastest-Growing Stocks on the Planet</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n5 of the Fastest-Growing Stocks on the Planet\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-27 19:22 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/07/27/5-of-the-fastest-growing-stocks-on-the-planet/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>For over 12 years, growth stocks have been the talk of Wall Street -- and with good reason. Persistently low lending rates have allowed fast-growing companies abundant access to cheap capital that ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/07/27/5-of-the-fastest-growing-stocks-on-the-planet/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://www.fool.com/investing/2021/07/27/5-of-the-fastest-growing-stocks-on-the-planet/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2154099201","content_text":"For over 12 years, growth stocks have been the talk of Wall Street -- and with good reason. Persistently low lending rates have allowed fast-growing companies abundant access to cheap capital that they've been able to use to hire new employees, acquire other businesses, and innovate for the future. With the nation's central bank standing firm on its monetary policy, at least in the near-term, growth stocks should continue to thrive.\nOf course, not all growth stocks are created equally. The following five companies are projected by Wall Street to be some of the fastest-growing stocks on the planet over the next four or five years, assuming analysts' sales projections (per FactSet) come to fruition.\nImage source: Getty Images.\nSnowflake: Implied five-year sales growth of 819%\nAmong cloud stocks, you'd struggle to find a company with a persistently higher annualized growth rate than Snowflake (NYSE:SNOW). After bringing in $592 million in full-year sales in fiscal 2021, Wall Street is looking for the company to deliver $5.44 billion in annual sales in fiscal 2026.\nWhat really has Wall Street excited are Snowflake's plain-as-day competitive advantages. Most notably, its cloud data-warehousing solutions are layered atop the most-popular infrastructure storage solutions. Whereas it can be difficult for businesses to share data that's stored on competing cloud service providers, this sharing of information is seamless for Snowflake's customers.\nSnowflake also shunned the subscription-based operating model in favor of a pay-as-you-go model. By charging its clients for the amount of data stored and the number of Snowflake Compute Credits used, the company is making its pricing transparent and potentially more cost-effective for users.\nWhile there's no question Snowflake is one of the fastest-growing stocks on the planet, where the company's stock should be valued is debatable. Though some premium is merited for such consistently high growth rates, I'm not so sure paying 71 times sales for this year makes sense for a company that's still many years away from profitability. There may not be significant downside here, but I also fail to see how this valuation stretches much further to the upside.\nImage source: Getty Images.\nTeladoc Health: Implied five-year sales growth of 416%\nHealthcare stocks on the leading edge of innovation are a pretty good bet to be among the fastest-growing stocks on the planet through mid-decade. Telehealth services giant Teladoc Health (NYSE:TDOC) is expected to see its annual sales climb from a reported $1.09 billion in 2020 to an estimated $5.62 billion by 2025. That's an increase of 416%, for those of you keeping score at home.\nEven though Teladoc found itself in an ideal scenario in 2020, with the coronavirus pandemic wreaking havoc in the U.S., this was a company growing sales by an annualized average of 74% in the six years leading up to the pandemic. In other words, we're clearly not talking about a one-hit wonder.\nTelemedicine is the future of healthcare in the U.S. and globally. While not all appointments can be conducted virtually, telehealth visits will provide added convenience for patients and make it considerably easier for doctor's to keep tabs on patients with chronic illnesses. This ease-of-use should result in improved patient outcomes, which'll mean less money out of the pockets of insurers.\nTeladoc's rapid growth is also a function of its buyout of applied health signals company Livongo Health in the fourth quarter. Livongo leans on artificial intelligence to send its chronically ill members tips to help them lead healthier lives. It ended the first quarter with 658,000 diabetes members, and the company was already profitable before being bought out by Teladoc. As a combined company, this duo looks unstoppable.\nImage source: Square.\nSquare: Implied five-year sales growth of 299%\nFintech stock Square (NYSE:SQ) is also projected to be one of the fastest-growing companies on the planet through the midpoint of the decade. Following its sales surge in 2020 to $9.5 billion, Wall Street's consensus for 2025 is that it'll bring in $37.86 billion. That's a hair shy of a quadrupling in sales in five years.\nSquare's most foundational growth driver, its seller ecosystem, will continue to point the needle higher. The amount of gross payment volume (GPV) traversing its network grew by an annualized average of 49% in the seven years leading up to the pandemic, but tailed off considerably in 2020 as merchants closed up shop due to the pandemic. With the U.S. economy reopening, Square looks to be on track for strong double-digit GPV growth this year.\nHowever, the company's key growth driver is digital peer-to-peer platform Cash App. Cash App's monthly active user count more than quintupled since the end of 2017 to 36 million, and it's been a consistently more popular download than PayPal's Venmo.  All told, Cash App allows Square to generate revenue from bank transfers, merchant purchases, and investments, which includes Bitcoin exchange and trading.\nAs of the end of 2020, the typical Cash App user was generating $41 in gross profit for Square, compared to less than $5 to acquire each new monthly active user. That's a heck of a trade-off that should make Square's shareholders very happy.\nImage source: Getty Images.\nJushi Holdings: Implied four-year sales growth of 1,100%\nThe U.S. cannabis industry is home to a number of companies that'll deliver triple-digit sales growth over the next four or five years. But marijuana stock Jushi Holdings (OTC:JUSHF) might have them all beat, with sales growth expected to hit 1,100% by 2024 ($81 million in 2020 to $972 million in 2024).\nCompared to other multistate operators, Jushi is a tiny tot. It has 20 operational dispensaries at the moment, with 13 of those retail locations in Pennsylvania. The real key to Jushi's strategy is targeting markets that offer some level of competitive protection. That's why it's chosen to focus on Pennsylvania, Illinois, and Virginia.\nWhile all three of these markets offer billion-dollar annual sales potential -- Illinois surpassed $1 billion in weed sales for the first time in 2020 -- the real lure is that they limit how many retail licenses are issued in total, as well as to individual businesses. Pennsylvania and Illinois have preset caps in place, whereas Virginia assigns licenses based on jurisdiction. This effectively limits Jushi's competition and ensures it'll be able to build up its brand and grab a loyal following.\nInvestors should also note that, despite its relatively small market cap, Jushi isn't afraid to go shopping. In January, the company acquired two dispensaries in California, the largest weed market in the world by annual sales.  It also bought its way into Nevada in April.  The Silver State is projected to lead the country in cannabis spending per capita by mid-decade. In other words, smart planning by management has Jushi set up for some serious growth.\nA Tesla Model S plugged in for charging. Image source: Tesla.\nTesla Motors: Implied five-year sales growth of 270%\nA final company most investors know well that has supercharged growth potential over the next five years is electric vehicle (EV) manufacturer Tesla Motors (NASDAQ:TSLA). Tesla brought in $31.5 billion in full-year sales in 2020, but Wall Street's consensus has the company pegged for $116.64 billion in sales by 2025.\nTesla is a clear and obvious beneficiary of the U.S. and most developed countries wanting to pursue cleaner energy solutions in order to reduce long-term carbon dioxide emissions. It's the first automaker in more than five decades to successfully build itself from the ground up to mass production, and it offers definitive first-mover advantages in the United States.\nIn particular, Tesla Motors' battery technology remains unsurpassed, at least for the time being. The company's batteries have better range, more power, and higher capacity than the competition. Considering that cash is no longer a concern, the company has more than enough capital to continue constructing new Gigafactories to assemble its vehicles and produce batteries.\nBut like Snowflake, valuation is a serious concern. You'd think a company with a $620 billion market cap, as of this past weekend, would be able to generate a profit from the products or services it sells. That's not the case with Tesla. Its adjusted profits have always come from selling renewable energy credits to other automakers or selling its digital assets (Bitcoin) for a profit. Based solely on its operating performance, Tesla still isn't making money. That makes its existing valuation dicey, at best.","news_type":1,"symbols_score_info":{"JUSHF":0.9,"SNOW":0.9,"SQ":0.9,"TDOC":0.9,"TSLA":0.9}},"isVote":1,"tweetType":1,"viewCount":394,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":803088792,"gmtCreate":1627396579816,"gmtModify":1631892526696,"author":{"id":"3571282373975763","authorId":"3571282373975763","name":"Asher123","avatar":"https://static.tigerbbs.com/36d4977f7e84ecc5a126c24c142136ca","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3571282373975763","authorIdStr":"3571282373975763"},"themes":[],"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/803088792","repostId":"2154099201","repostType":4,"repost":{"id":"2154099201","kind":"highlight","pubTimestamp":1627384921,"share":"https://ttm.financial/m/news/2154099201?lang=&edition=full","pubTime":"2021-07-27 19:22","market":"us","language":"en","title":"5 of the Fastest-Growing Stocks on the Planet","url":"https://stock-news.laohu8.com/highlight/detail?id=2154099201","media":"Motley Fool","summary":"Sales for these companies are expected to increase between 270% and 1,100% over the next four or five years.","content":"<p>For over 12 years, growth stocks have been the talk of Wall Street -- and with good reason. Persistently low lending rates have allowed fast-growing companies abundant access to cheap capital that they've been able to use to hire new employees, acquire other businesses, and innovate for the future. With the nation's central bank standing firm on its monetary policy, at least in the near-term, growth stocks should continue to thrive.</p>\n<p>Of course, not all growth stocks are created equally. The following five companies are projected by Wall Street to be some of the fastest-growing stocks on the planet over the next four or five years, assuming analysts' sales projections (per <b>FactSet</b>) come to fruition.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/ccad26103b3c97bbb65d0cad160f21b9\" tg-width=\"700\" tg-height=\"489\" width=\"100%\" height=\"auto\"><span>Image source: Getty Images.</span></p>\n<h2><a href=\"https://laohu8.com/S/SNOW\">Snowflake</a>: Implied five-year sales growth of 819%</h2>\n<p>Among cloud stocks, you'd struggle to find a company with a persistently higher annualized growth rate than <b>Snowflake</b> (NYSE:SNOW). After bringing in $592 million in full-year sales in fiscal 2021, Wall Street is looking for the company to deliver $5.44 billion in annual sales in fiscal 2026.</p>\n<p>What really has Wall Street excited are Snowflake's plain-as-day competitive advantages. Most notably, its cloud data-warehousing solutions are layered atop the most-popular infrastructure storage solutions. Whereas it can be difficult for businesses to share data that's stored on competing cloud service providers, this sharing of information is seamless for Snowflake's customers.</p>\n<p>Snowflake also shunned the subscription-based operating model in favor of a pay-as-you-go model. By charging its clients for the amount of data stored and the number of Snowflake Compute Credits used, the company is making its pricing transparent and potentially more cost-effective for users.</p>\n<p>While there's no question Snowflake is <a href=\"https://laohu8.com/S/AONE.U\">one</a> of the fastest-growing stocks on the planet, where the company's stock should be valued is debatable. Though some premium is merited for such consistently high growth rates, I'm not so sure paying 71 times sales for this year makes sense for a company that's still many years away from profitability. There may not be significant downside here, but I also fail to see how this valuation stretches much further to the upside.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/df219df7b01fbc2aa008c455f28b99e5\" tg-width=\"700\" tg-height=\"466\" width=\"100%\" height=\"auto\"><span>Image source: Getty Images.</span></p>\n<h2>Teladoc Health: Implied five-year sales growth of 416%</h2>\n<p>Healthcare stocks on the leading edge of innovation are a pretty good bet to be among the fastest-growing stocks on the planet through mid-decade. Telehealth services giant <b>Teladoc Health</b> (NYSE:TDOC) is expected to see its annual sales climb from a reported $1.09 billion in 2020 to an estimated $5.62 billion by 2025. That's an increase of 416%, for those of you keeping score at home.</p>\n<p>Even though Teladoc found itself in an ideal scenario in 2020, with the coronavirus pandemic wreaking havoc in the U.S., this was a company growing sales by an annualized average of 74% in the six years leading up to the pandemic. In other words, we're clearly not talking about a one-hit wonder.</p>\n<p>Telemedicine is the future of healthcare in the U.S. and globally. While not all appointments can be conducted virtually, telehealth visits will provide added convenience for patients and make it considerably easier for doctor's to keep tabs on patients with chronic illnesses. This ease-of-use should result in improved patient outcomes, which'll mean less money out of the pockets of insurers.</p>\n<p>Teladoc's rapid growth is also a function of its buyout of applied health signals company Livongo Health in the fourth quarter. Livongo leans on artificial intelligence to send its chronically ill members tips to help them lead healthier lives. It ended the first quarter with 658,000 diabetes members, and the company was already profitable before being bought out by Teladoc. As a combined company, this duo looks unstoppable.</p>\n<p class=\"t-img-caption\"><img src=\"https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F635018%2Fsquare-cash-card-cash-app.jpg&amp;w=700&amp;op=resize\" tg-width=\"700\" tg-height=\"520\" width=\"100%\" height=\"auto\"><span>Image source: Square.</span></p>\n<h2>Square: Implied five-year sales growth of 299%</h2>\n<p>Fintech stock <b>Square</b> (NYSE:SQ) is also projected to be one of the fastest-growing companies on the planet through the midpoint of the decade. Following its sales surge in 2020 to $9.5 billion, Wall Street's consensus for 2025 is that it'll bring in $37.86 billion. That's a hair shy of a quadrupling in sales in five years.</p>\n<p>Square's most foundational growth driver, its seller ecosystem, will continue to point the needle higher. The amount of gross payment volume (GPV) traversing its network grew by an annualized average of 49% in the seven years leading up to the pandemic, but tailed off considerably in 2020 as merchants closed up shop due to the pandemic. With the U.S. economy reopening, Square looks to be on track for strong double-digit GPV growth this year.</p>\n<p>However, the company's key growth driver is digital peer-to-peer platform Cash App. Cash App's monthly active user count more than quintupled since the end of 2017 to 36 million, and it's been a consistently more popular download than <b><a href=\"https://laohu8.com/S/PYPL\">PayPal</a></b>'s Venmo.&nbsp; All told, Cash App allows Square to generate revenue from bank transfers, merchant purchases, and investments, which includes <b>Bitcoin</b>&nbsp;exchange and trading.</p>\n<p>As of the end of 2020, the typical Cash App user was generating $41 in gross profit for Square, compared to less than $5 to acquire each new monthly active user. That's a heck of a trade-off that should make Square's shareholders very happy.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/75c8c7cdfeae935529dbccbf6b0c507c\" tg-width=\"700\" tg-height=\"490\" width=\"100%\" height=\"auto\"><span>Image source: Getty Images.</span></p>\n<h2>Jushi Holdings: Implied four-year sales growth of 1,100%</h2>\n<p>The U.S. cannabis industry is home to a number of companies that'll deliver triple-digit sales growth over the next four or five years. But marijuana stock <b>Jushi Holdings</b> (OTC:JUSHF) might have them all beat, with sales growth expected to hit 1,100% by 2024 ($81 million in 2020 to $972 million in 2024).</p>\n<p>Compared to other multistate operators, Jushi is a tiny tot. It has 20 operational dispensaries at the moment, with 13 of those retail locations in Pennsylvania. The real key to Jushi's strategy is targeting markets that offer some level of competitive protection. That's why it's chosen to focus on Pennsylvania, Illinois, and Virginia.</p>\n<p>While all three of these markets offer billion-dollar annual sales potential -- Illinois surpassed $1 billion in weed sales for the first time in 2020 -- the real lure is that they limit how many retail licenses are issued in total, as well as to individual businesses. Pennsylvania and Illinois have preset caps in place, whereas Virginia assigns licenses based on jurisdiction. This effectively limits Jushi's competition and ensures it'll be able to build up its brand and grab a loyal following.</p>\n<p>Investors should also note that, despite its relatively small market cap, Jushi isn't afraid to go shopping. In January, the company acquired two dispensaries in California, the largest weed market in the world by annual sales.&nbsp; It also bought its way into Nevada in April.&nbsp; The Silver State is projected to lead the country in cannabis spending per capita by mid-decade. In other words, smart planning by management has Jushi set up for some serious growth.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/2bd808070a9dde55f37210b59edc2e23\" tg-width=\"700\" tg-height=\"393\" width=\"100%\" height=\"auto\"><span>A Tesla Model S plugged in for charging. Image source: Tesla.</span></p>\n<h2>Tesla Motors: Implied five-year sales growth of 270%</h2>\n<p>A final company most investors know well that has supercharged growth potential over the next five years is electric vehicle (EV) manufacturer <b>Tesla Motors</b> (NASDAQ:TSLA). Tesla brought in $31.5 billion in full-year sales in 2020, but Wall Street's consensus has the company pegged for $116.64 billion in sales by 2025.</p>\n<p>Tesla is a clear and obvious beneficiary of the U.S. and most developed countries wanting to pursue cleaner energy solutions in order to reduce long-term carbon dioxide emissions. It's the first automaker in more than five decades to successfully build itself from the ground up to mass production, and it offers definitive first-mover advantages in the United States.</p>\n<p>In particular, Tesla Motors' battery technology remains unsurpassed, at least for the time being. The company's batteries have better range, more power, and higher capacity than the competition. Considering that cash is no longer a concern, the company has more than enough capital to continue constructing new Gigafactories to assemble its vehicles and produce batteries.</p>\n<p>But like Snowflake, valuation is a serious concern. You'd think a company with a $620 billion market cap, as of this past weekend, would be able to generate a profit from the products or services it sells. That's not the case with Tesla. Its adjusted profits have always come from selling renewable energy credits to other automakers or selling its digital assets (Bitcoin) for a profit. Based solely on its operating performance, Tesla still isn't making money. That makes its existing valuation dicey, at best.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>5 of the Fastest-Growing Stocks on the Planet</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n5 of the Fastest-Growing Stocks on the Planet\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-27 19:22 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/07/27/5-of-the-fastest-growing-stocks-on-the-planet/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>For over 12 years, growth stocks have been the talk of Wall Street -- and with good reason. Persistently low lending rates have allowed fast-growing companies abundant access to cheap capital that ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/07/27/5-of-the-fastest-growing-stocks-on-the-planet/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://www.fool.com/investing/2021/07/27/5-of-the-fastest-growing-stocks-on-the-planet/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2154099201","content_text":"For over 12 years, growth stocks have been the talk of Wall Street -- and with good reason. Persistently low lending rates have allowed fast-growing companies abundant access to cheap capital that they've been able to use to hire new employees, acquire other businesses, and innovate for the future. With the nation's central bank standing firm on its monetary policy, at least in the near-term, growth stocks should continue to thrive.\nOf course, not all growth stocks are created equally. The following five companies are projected by Wall Street to be some of the fastest-growing stocks on the planet over the next four or five years, assuming analysts' sales projections (per FactSet) come to fruition.\nImage source: Getty Images.\nSnowflake: Implied five-year sales growth of 819%\nAmong cloud stocks, you'd struggle to find a company with a persistently higher annualized growth rate than Snowflake (NYSE:SNOW). After bringing in $592 million in full-year sales in fiscal 2021, Wall Street is looking for the company to deliver $5.44 billion in annual sales in fiscal 2026.\nWhat really has Wall Street excited are Snowflake's plain-as-day competitive advantages. Most notably, its cloud data-warehousing solutions are layered atop the most-popular infrastructure storage solutions. Whereas it can be difficult for businesses to share data that's stored on competing cloud service providers, this sharing of information is seamless for Snowflake's customers.\nSnowflake also shunned the subscription-based operating model in favor of a pay-as-you-go model. By charging its clients for the amount of data stored and the number of Snowflake Compute Credits used, the company is making its pricing transparent and potentially more cost-effective for users.\nWhile there's no question Snowflake is one of the fastest-growing stocks on the planet, where the company's stock should be valued is debatable. Though some premium is merited for such consistently high growth rates, I'm not so sure paying 71 times sales for this year makes sense for a company that's still many years away from profitability. There may not be significant downside here, but I also fail to see how this valuation stretches much further to the upside.\nImage source: Getty Images.\nTeladoc Health: Implied five-year sales growth of 416%\nHealthcare stocks on the leading edge of innovation are a pretty good bet to be among the fastest-growing stocks on the planet through mid-decade. Telehealth services giant Teladoc Health (NYSE:TDOC) is expected to see its annual sales climb from a reported $1.09 billion in 2020 to an estimated $5.62 billion by 2025. That's an increase of 416%, for those of you keeping score at home.\nEven though Teladoc found itself in an ideal scenario in 2020, with the coronavirus pandemic wreaking havoc in the U.S., this was a company growing sales by an annualized average of 74% in the six years leading up to the pandemic. In other words, we're clearly not talking about a one-hit wonder.\nTelemedicine is the future of healthcare in the U.S. and globally. While not all appointments can be conducted virtually, telehealth visits will provide added convenience for patients and make it considerably easier for doctor's to keep tabs on patients with chronic illnesses. This ease-of-use should result in improved patient outcomes, which'll mean less money out of the pockets of insurers.\nTeladoc's rapid growth is also a function of its buyout of applied health signals company Livongo Health in the fourth quarter. Livongo leans on artificial intelligence to send its chronically ill members tips to help them lead healthier lives. It ended the first quarter with 658,000 diabetes members, and the company was already profitable before being bought out by Teladoc. As a combined company, this duo looks unstoppable.\nImage source: Square.\nSquare: Implied five-year sales growth of 299%\nFintech stock Square (NYSE:SQ) is also projected to be one of the fastest-growing companies on the planet through the midpoint of the decade. Following its sales surge in 2020 to $9.5 billion, Wall Street's consensus for 2025 is that it'll bring in $37.86 billion. That's a hair shy of a quadrupling in sales in five years.\nSquare's most foundational growth driver, its seller ecosystem, will continue to point the needle higher. The amount of gross payment volume (GPV) traversing its network grew by an annualized average of 49% in the seven years leading up to the pandemic, but tailed off considerably in 2020 as merchants closed up shop due to the pandemic. With the U.S. economy reopening, Square looks to be on track for strong double-digit GPV growth this year.\nHowever, the company's key growth driver is digital peer-to-peer platform Cash App. Cash App's monthly active user count more than quintupled since the end of 2017 to 36 million, and it's been a consistently more popular download than PayPal's Venmo.  All told, Cash App allows Square to generate revenue from bank transfers, merchant purchases, and investments, which includes Bitcoin exchange and trading.\nAs of the end of 2020, the typical Cash App user was generating $41 in gross profit for Square, compared to less than $5 to acquire each new monthly active user. That's a heck of a trade-off that should make Square's shareholders very happy.\nImage source: Getty Images.\nJushi Holdings: Implied four-year sales growth of 1,100%\nThe U.S. cannabis industry is home to a number of companies that'll deliver triple-digit sales growth over the next four or five years. But marijuana stock Jushi Holdings (OTC:JUSHF) might have them all beat, with sales growth expected to hit 1,100% by 2024 ($81 million in 2020 to $972 million in 2024).\nCompared to other multistate operators, Jushi is a tiny tot. It has 20 operational dispensaries at the moment, with 13 of those retail locations in Pennsylvania. The real key to Jushi's strategy is targeting markets that offer some level of competitive protection. That's why it's chosen to focus on Pennsylvania, Illinois, and Virginia.\nWhile all three of these markets offer billion-dollar annual sales potential -- Illinois surpassed $1 billion in weed sales for the first time in 2020 -- the real lure is that they limit how many retail licenses are issued in total, as well as to individual businesses. Pennsylvania and Illinois have preset caps in place, whereas Virginia assigns licenses based on jurisdiction. This effectively limits Jushi's competition and ensures it'll be able to build up its brand and grab a loyal following.\nInvestors should also note that, despite its relatively small market cap, Jushi isn't afraid to go shopping. In January, the company acquired two dispensaries in California, the largest weed market in the world by annual sales.  It also bought its way into Nevada in April.  The Silver State is projected to lead the country in cannabis spending per capita by mid-decade. In other words, smart planning by management has Jushi set up for some serious growth.\nA Tesla Model S plugged in for charging. Image source: Tesla.\nTesla Motors: Implied five-year sales growth of 270%\nA final company most investors know well that has supercharged growth potential over the next five years is electric vehicle (EV) manufacturer Tesla Motors (NASDAQ:TSLA). Tesla brought in $31.5 billion in full-year sales in 2020, but Wall Street's consensus has the company pegged for $116.64 billion in sales by 2025.\nTesla is a clear and obvious beneficiary of the U.S. and most developed countries wanting to pursue cleaner energy solutions in order to reduce long-term carbon dioxide emissions. It's the first automaker in more than five decades to successfully build itself from the ground up to mass production, and it offers definitive first-mover advantages in the United States.\nIn particular, Tesla Motors' battery technology remains unsurpassed, at least for the time being. The company's batteries have better range, more power, and higher capacity than the competition. Considering that cash is no longer a concern, the company has more than enough capital to continue constructing new Gigafactories to assemble its vehicles and produce batteries.\nBut like Snowflake, valuation is a serious concern. You'd think a company with a $620 billion market cap, as of this past weekend, would be able to generate a profit from the products or services it sells. That's not the case with Tesla. Its adjusted profits have always come from selling renewable energy credits to other automakers or selling its digital assets (Bitcoin) for a profit. Based solely on its operating performance, Tesla still isn't making money. That makes its existing valuation dicey, at best.","news_type":1,"symbols_score_info":{"JUSHF":0.9,"SNOW":0.9,"SQ":0.9,"TDOC":0.9,"TSLA":0.9}},"isVote":1,"tweetType":1,"viewCount":493,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":145077522,"gmtCreate":1626184871566,"gmtModify":1631892526708,"author":{"id":"3571282373975763","authorId":"3571282373975763","name":"Asher123","avatar":"https://static.tigerbbs.com/36d4977f7e84ecc5a126c24c142136ca","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3571282373975763","authorIdStr":"3571282373975763"},"themes":[],"htmlText":"Liking this","listText":"Liking this","text":"Liking this","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/145077522","repostId":"2151565201","repostType":4,"repost":{"id":"2151565201","kind":"highlight","weMediaInfo":{"introduction":"The leading daily newsletter for the latest financial and business news. 33Yrs Helping Stock Investors with Investing Insights, Tools, News & More.","home_visible":0,"media_name":"Investors","id":"1085713068","head_image":"https://static.tigerbbs.com/608dd68a89ed486e18f64efe3136266c"},"pubTimestamp":1626177299,"share":"https://ttm.financial/m/news/2151565201?lang=&edition=full","pubTime":"2021-07-13 19:54","market":"us","language":"en","title":"10 Companies Are About To Post Blowout 1,000%+ Profit Growth","url":"https://stock-news.laohu8.com/highlight/detail?id=2151565201","media":"Investors","summary":"S&P 500 investors are waiting for banner profit reports to kick off this week. And some companies' profit gains are likely to be enormous.","content":"<p>S&amp;P 500 investors are waiting for banner profit reports to kick off this week. And some companies' profit gains are likely to be more enormous than others.</p>\n<p>Analysts expect 10 S&amp;P 500 companies, including health care <b>Zimmer Biomet</b>, energy firm <b>Freeport-McMoRan</b> and consumer discretionary firm <b>Chipotle Mexican Grill</b>, to post massive adjusted profit per share growth of 1,000% or much more for the second quarter. And that would make these companies S&amp;P 500 standouts in a quarter already expected to be a massive <a href=\"https://laohu8.com/S/AONE\">one</a> for profit growth, says an Investor's Business Daily analysis of data from S&amp;P Global Market Intelligence and MarketSmith.</p>\n<p>\"We ran out of superlatives to describe corporate America's stunning performance during first-quarter earnings season,\" said Jeff Buchbinder, equity strategist at LPL Financial. \"So what will companies do for an encore? We expect more good news this quarter as more of the economy has opened up, while also acknowledging the second quarter will almost certainly end up being the peak in earnings growth for this cycle.\"</p>\n<p>Profit reports kick off this week with the banks. And what a peak it'll be for S&amp;P 50o profit.</p>\n<h2>S&amp;P 500 Headed To Amazing Quarterly Profit</h2>\n<p>Companies in the S&amp;P 500 are expected to post moonshot quarterly profit growth of 64% in the second quarter, says John Butters, earnings analyst at FactSet. If that's right, it would be the largest quarterly profit posted by the S&amp;P 500 in more than a decade, Butters says.</p>\n<p>Profits are soaring back as the U.S. economy is reopening, jobs are plentiful and companies and consumers have lots of money to spend. And the speed of the economy's rebound surprised most people. Analysts bumped up their profit forecasts for the quarter 7.2% since the end of March through June 30. That's the largest upward profit growth forecast boost since FactSet has tracked it going back to 2002, Butters says.</p>\n<p>Skeptics might think this is just wishful thinking. But early indications show there's reason to be optimistic. Already 66 S&amp;P 500 companies, also a record, said second-quarter profit will top their earlier targets.</p>\n<p>So how you stand out when most companies' profits are booming? Just ask 10 S&amp;P 500 outliers.</p>\n<h2>Putting Up 1,000% Or More Profit Growth</h2>\n<p>Scanning the S&amp;P 500, Zimmer Biomet is the company to beat in terms of profit growth. Analysts think it will earn $1.86 a share on an adjusted basis in the second quarter. That's up more than 3,600% from what it earned in the same period a year ago.</p>\n<p>The company makes a variety of orthopedic products like hip and knee replacements. Demand for such goods is expected to be strong as many people now get the optional procedures they put off during the pandemic. Zimmer Biomet reports its second quarter profit on Aug. 3. Shares are only up 3.8% this year so far.</p>\n<p>Energy, though, is an area where profits and share prices are booming. Shares of copper miner Freeport-McMoRan are up more than 40% as investors anticipate an amazing quarter for profits. Analysts are calling for the company to earn nearly 74 cents a share in the second quarter, up more than 2,350% from the same year-ago period. Such strong fundamentals paired with a rising stock price explain the lofty 93 IBD Composite Rating. The company reports on July 22.</p>\n<p>And when it comes to a high Composite Rating, look at Chipotle. The burrito chain sports a near perfect IBD Composite Rating of 98. Shares are up 16.5% this year, roughly in line with the S&amp;P 500. But get ready for a hot-red quarter of profit growth. Analysts think it will report second-quarter profit growth of more than 1,517% or $6.47 a share. Chipotle reports on July 20.</p>\n<p>So while it's going to be a powerful period of growth for the S&amp;P 500, it's still possible to beat the average.</p>\n<h2>A Bonanza Of Profit Is Coming</h2>\n<p><i>Analysts see 1,000% or more profit growth from these S&amp;P 500 companies in the second quarter</i></p>\n<table>\n <thead>\n  <tr>\n   <th>Company</th>\n   <th>Ticker</th>\n   <th>Q2 EPS % Ch.</th>\n   <th>Primary Sector</th>\n   <th>Composite Rating</th>\n   <th>% stock YTD ch.</th>\n  </tr>\n </thead>\n <tbody>\n  <tr>\n   <td>Zimmer Biomet</td>\n   <td></td>\n   <td><b>3,620.0%</b></td>\n   <td>Health Care</td>\n   <td>39</td>\n   <td>3.8%</td>\n  </tr>\n  <tr>\n   <td>Freeport-McMoRan</td>\n   <td></td>\n   <td><b>2,353.3%</b></td>\n   <td>Materials</td>\n   <td>93</td>\n   <td>40.4%</td>\n  </tr>\n  <tr>\n   <td>Hasbro</td>\n   <td></td>\n   <td><b>2,285.0%</b></td>\n   <td>Consumer Discretionary</td>\n   <td>67</td>\n   <td>4.9%</td>\n  </tr>\n  <tr>\n   <td><a href=\"https://laohu8.com/S/SYF\">Synchrony Financial</a></td>\n   <td></td>\n   <td><b>2,150.0%</b></td>\n   <td>Financials</td>\n   <td>88</td>\n   <td>40.4%</td>\n  </tr>\n  <tr>\n   <td>W. R. Berkley</td>\n   <td></td>\n   <td><b>1,525.0%</b></td>\n   <td>Financials</td>\n   <td>71</td>\n   <td>14.8%</td>\n  </tr>\n  <tr>\n   <td>Chipotle Mexican Grill</td>\n   <td></td>\n   <td><b>1,517.5%</b></td>\n   <td>Consumer Discretionary</td>\n   <td>98</td>\n   <td>16.5%</td>\n  </tr>\n  <tr>\n   <td>Ross Stores</td>\n   <td></td>\n   <td><b>1,460.0%</b></td>\n   <td>Consumer Discretionary</td>\n   <td>72</td>\n   <td>1.1%</td>\n  </tr>\n  <tr>\n   <td><a href=\"https://laohu8.com/S/FANG\">Diamondback Energy</a></td>\n   <td></td>\n   <td><b>1,306.7%</b></td>\n   <td>Energy</td>\n   <td>97</td>\n   <td>85.6%</td>\n  </tr>\n  <tr>\n   <td>Nucor</td>\n   <td></td>\n   <td><b>1,179.6%</b></td>\n   <td>Materials</td>\n   <td>98</td>\n   <td>83.8%</td>\n  </tr>\n  <tr>\n   <td>Weyerhaeuser</td>\n   <td></td>\n   <td><b>1,109.1%</b></td>\n   <td>Real Estate</td>\n   <td>87</td>\n   <td>6.3%</td>\n  </tr>\n </tbody>\n</table>\n<h5>Sources: IBD, S&amp;P Global Market Intelligence</h5>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>10 Companies Are About To Post Blowout 1,000%+ Profit Growth</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n10 Companies Are About To Post Blowout 1,000%+ Profit Growth\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/608dd68a89ed486e18f64efe3136266c);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Investors </p>\n<p class=\"h-time\">2021-07-13 19:54</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<p>S&amp;P 500 investors are waiting for banner profit reports to kick off this week. And some companies' profit gains are likely to be more enormous than others.</p>\n<p>Analysts expect 10 S&amp;P 500 companies, including health care <b>Zimmer Biomet</b>, energy firm <b>Freeport-McMoRan</b> and consumer discretionary firm <b>Chipotle Mexican Grill</b>, to post massive adjusted profit per share growth of 1,000% or much more for the second quarter. And that would make these companies S&amp;P 500 standouts in a quarter already expected to be a massive <a href=\"https://laohu8.com/S/AONE\">one</a> for profit growth, says an Investor's Business Daily analysis of data from S&amp;P Global Market Intelligence and MarketSmith.</p>\n<p>\"We ran out of superlatives to describe corporate America's stunning performance during first-quarter earnings season,\" said Jeff Buchbinder, equity strategist at LPL Financial. \"So what will companies do for an encore? We expect more good news this quarter as more of the economy has opened up, while also acknowledging the second quarter will almost certainly end up being the peak in earnings growth for this cycle.\"</p>\n<p>Profit reports kick off this week with the banks. And what a peak it'll be for S&amp;P 50o profit.</p>\n<h2>S&amp;P 500 Headed To Amazing Quarterly Profit</h2>\n<p>Companies in the S&amp;P 500 are expected to post moonshot quarterly profit growth of 64% in the second quarter, says John Butters, earnings analyst at FactSet. If that's right, it would be the largest quarterly profit posted by the S&amp;P 500 in more than a decade, Butters says.</p>\n<p>Profits are soaring back as the U.S. economy is reopening, jobs are plentiful and companies and consumers have lots of money to spend. And the speed of the economy's rebound surprised most people. Analysts bumped up their profit forecasts for the quarter 7.2% since the end of March through June 30. That's the largest upward profit growth forecast boost since FactSet has tracked it going back to 2002, Butters says.</p>\n<p>Skeptics might think this is just wishful thinking. But early indications show there's reason to be optimistic. Already 66 S&amp;P 500 companies, also a record, said second-quarter profit will top their earlier targets.</p>\n<p>So how you stand out when most companies' profits are booming? Just ask 10 S&amp;P 500 outliers.</p>\n<h2>Putting Up 1,000% Or More Profit Growth</h2>\n<p>Scanning the S&amp;P 500, Zimmer Biomet is the company to beat in terms of profit growth. Analysts think it will earn $1.86 a share on an adjusted basis in the second quarter. That's up more than 3,600% from what it earned in the same period a year ago.</p>\n<p>The company makes a variety of orthopedic products like hip and knee replacements. Demand for such goods is expected to be strong as many people now get the optional procedures they put off during the pandemic. Zimmer Biomet reports its second quarter profit on Aug. 3. Shares are only up 3.8% this year so far.</p>\n<p>Energy, though, is an area where profits and share prices are booming. Shares of copper miner Freeport-McMoRan are up more than 40% as investors anticipate an amazing quarter for profits. Analysts are calling for the company to earn nearly 74 cents a share in the second quarter, up more than 2,350% from the same year-ago period. Such strong fundamentals paired with a rising stock price explain the lofty 93 IBD Composite Rating. The company reports on July 22.</p>\n<p>And when it comes to a high Composite Rating, look at Chipotle. The burrito chain sports a near perfect IBD Composite Rating of 98. Shares are up 16.5% this year, roughly in line with the S&amp;P 500. But get ready for a hot-red quarter of profit growth. Analysts think it will report second-quarter profit growth of more than 1,517% or $6.47 a share. Chipotle reports on July 20.</p>\n<p>So while it's going to be a powerful period of growth for the S&amp;P 500, it's still possible to beat the average.</p>\n<h2>A Bonanza Of Profit Is Coming</h2>\n<p><i>Analysts see 1,000% or more profit growth from these S&amp;P 500 companies in the second quarter</i></p>\n<table>\n <thead>\n  <tr>\n   <th>Company</th>\n   <th>Ticker</th>\n   <th>Q2 EPS % Ch.</th>\n   <th>Primary Sector</th>\n   <th>Composite Rating</th>\n   <th>% stock YTD ch.</th>\n  </tr>\n </thead>\n <tbody>\n  <tr>\n   <td>Zimmer Biomet</td>\n   <td></td>\n   <td><b>3,620.0%</b></td>\n   <td>Health Care</td>\n   <td>39</td>\n   <td>3.8%</td>\n  </tr>\n  <tr>\n   <td>Freeport-McMoRan</td>\n   <td></td>\n   <td><b>2,353.3%</b></td>\n   <td>Materials</td>\n   <td>93</td>\n   <td>40.4%</td>\n  </tr>\n  <tr>\n   <td>Hasbro</td>\n   <td></td>\n   <td><b>2,285.0%</b></td>\n   <td>Consumer Discretionary</td>\n   <td>67</td>\n   <td>4.9%</td>\n  </tr>\n  <tr>\n   <td><a href=\"https://laohu8.com/S/SYF\">Synchrony Financial</a></td>\n   <td></td>\n   <td><b>2,150.0%</b></td>\n   <td>Financials</td>\n   <td>88</td>\n   <td>40.4%</td>\n  </tr>\n  <tr>\n   <td>W. R. Berkley</td>\n   <td></td>\n   <td><b>1,525.0%</b></td>\n   <td>Financials</td>\n   <td>71</td>\n   <td>14.8%</td>\n  </tr>\n  <tr>\n   <td>Chipotle Mexican Grill</td>\n   <td></td>\n   <td><b>1,517.5%</b></td>\n   <td>Consumer Discretionary</td>\n   <td>98</td>\n   <td>16.5%</td>\n  </tr>\n  <tr>\n   <td>Ross Stores</td>\n   <td></td>\n   <td><b>1,460.0%</b></td>\n   <td>Consumer Discretionary</td>\n   <td>72</td>\n   <td>1.1%</td>\n  </tr>\n  <tr>\n   <td><a href=\"https://laohu8.com/S/FANG\">Diamondback Energy</a></td>\n   <td></td>\n   <td><b>1,306.7%</b></td>\n   <td>Energy</td>\n   <td>97</td>\n   <td>85.6%</td>\n  </tr>\n  <tr>\n   <td>Nucor</td>\n   <td></td>\n   <td><b>1,179.6%</b></td>\n   <td>Materials</td>\n   <td>98</td>\n   <td>83.8%</td>\n  </tr>\n  <tr>\n   <td>Weyerhaeuser</td>\n   <td></td>\n   <td><b>1,109.1%</b></td>\n   <td>Real Estate</td>\n   <td>87</td>\n   <td>6.3%</td>\n  </tr>\n </tbody>\n</table>\n<h5>Sources: IBD, S&amp;P Global Market Intelligence</h5>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2151565201","content_text":"S&P 500 investors are waiting for banner profit reports to kick off this week. And some companies' profit gains are likely to be more enormous than others.\nAnalysts expect 10 S&P 500 companies, including health care Zimmer Biomet, energy firm Freeport-McMoRan and consumer discretionary firm Chipotle Mexican Grill, to post massive adjusted profit per share growth of 1,000% or much more for the second quarter. And that would make these companies S&P 500 standouts in a quarter already expected to be a massive one for profit growth, says an Investor's Business Daily analysis of data from S&P Global Market Intelligence and MarketSmith.\n\"We ran out of superlatives to describe corporate America's stunning performance during first-quarter earnings season,\" said Jeff Buchbinder, equity strategist at LPL Financial. \"So what will companies do for an encore? We expect more good news this quarter as more of the economy has opened up, while also acknowledging the second quarter will almost certainly end up being the peak in earnings growth for this cycle.\"\nProfit reports kick off this week with the banks. And what a peak it'll be for S&P 50o profit.\nS&P 500 Headed To Amazing Quarterly Profit\nCompanies in the S&P 500 are expected to post moonshot quarterly profit growth of 64% in the second quarter, says John Butters, earnings analyst at FactSet. If that's right, it would be the largest quarterly profit posted by the S&P 500 in more than a decade, Butters says.\nProfits are soaring back as the U.S. economy is reopening, jobs are plentiful and companies and consumers have lots of money to spend. And the speed of the economy's rebound surprised most people. Analysts bumped up their profit forecasts for the quarter 7.2% since the end of March through June 30. That's the largest upward profit growth forecast boost since FactSet has tracked it going back to 2002, Butters says.\nSkeptics might think this is just wishful thinking. But early indications show there's reason to be optimistic. Already 66 S&P 500 companies, also a record, said second-quarter profit will top their earlier targets.\nSo how you stand out when most companies' profits are booming? Just ask 10 S&P 500 outliers.\nPutting Up 1,000% Or More Profit Growth\nScanning the S&P 500, Zimmer Biomet is the company to beat in terms of profit growth. Analysts think it will earn $1.86 a share on an adjusted basis in the second quarter. That's up more than 3,600% from what it earned in the same period a year ago.\nThe company makes a variety of orthopedic products like hip and knee replacements. Demand for such goods is expected to be strong as many people now get the optional procedures they put off during the pandemic. Zimmer Biomet reports its second quarter profit on Aug. 3. Shares are only up 3.8% this year so far.\nEnergy, though, is an area where profits and share prices are booming. Shares of copper miner Freeport-McMoRan are up more than 40% as investors anticipate an amazing quarter for profits. Analysts are calling for the company to earn nearly 74 cents a share in the second quarter, up more than 2,350% from the same year-ago period. Such strong fundamentals paired with a rising stock price explain the lofty 93 IBD Composite Rating. The company reports on July 22.\nAnd when it comes to a high Composite Rating, look at Chipotle. The burrito chain sports a near perfect IBD Composite Rating of 98. Shares are up 16.5% this year, roughly in line with the S&P 500. But get ready for a hot-red quarter of profit growth. Analysts think it will report second-quarter profit growth of more than 1,517% or $6.47 a share. Chipotle reports on July 20.\nSo while it's going to be a powerful period of growth for the S&P 500, it's still possible to beat the average.\nA Bonanza Of Profit Is Coming\nAnalysts see 1,000% or more profit growth from these S&P 500 companies in the second quarter\n\n\n\nCompany\nTicker\nQ2 EPS % Ch.\nPrimary Sector\nComposite Rating\n% stock YTD ch.\n\n\n\n\nZimmer Biomet\n\n3,620.0%\nHealth Care\n39\n3.8%\n\n\nFreeport-McMoRan\n\n2,353.3%\nMaterials\n93\n40.4%\n\n\nHasbro\n\n2,285.0%\nConsumer Discretionary\n67\n4.9%\n\n\nSynchrony Financial\n\n2,150.0%\nFinancials\n88\n40.4%\n\n\nW. R. Berkley\n\n1,525.0%\nFinancials\n71\n14.8%\n\n\nChipotle Mexican Grill\n\n1,517.5%\nConsumer Discretionary\n98\n16.5%\n\n\nRoss Stores\n\n1,460.0%\nConsumer Discretionary\n72\n1.1%\n\n\nDiamondback Energy\n\n1,306.7%\nEnergy\n97\n85.6%\n\n\nNucor\n\n1,179.6%\nMaterials\n98\n83.8%\n\n\nWeyerhaeuser\n\n1,109.1%\nReal Estate\n87\n6.3%\n\n\n\nSources: IBD, S&P Global Market Intelligence","news_type":1,"symbols_score_info":{"CMG":0.9,"FCX":0.9,"POST":0.9,"ZBH":0.9}},"isVote":1,"tweetType":1,"viewCount":274,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":140652058,"gmtCreate":1625656377174,"gmtModify":1631892526718,"author":{"id":"3571282373975763","authorId":"3571282373975763","name":"Asher123","avatar":"https://static.tigerbbs.com/36d4977f7e84ecc5a126c24c142136ca","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3571282373975763","authorIdStr":"3571282373975763"},"themes":[],"htmlText":"Interesting&nbsp;","listText":"Interesting&nbsp;","text":"Interesting","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/140652058","repostId":"2149365051","repostType":4,"repost":{"id":"2149365051","kind":"highlight","pubTimestamp":1625648700,"share":"https://ttm.financial/m/news/2149365051?lang=&edition=full","pubTime":"2021-07-07 17:05","market":"us","language":"en","title":"3 Biotechs to Avoid Like the Plague in July","url":"https://stock-news.laohu8.com/highlight/detail?id=2149365051","media":"Motley Fool","summary":"Generally speaking, biotech is a pretty innovative industry -- with a few notable bad apples.","content":"<p>Biotech is an industry that has deeply enriched investors' pockets and helped numerous patients alike -- most recently in the form of coronavirus vaccine companies working to contain the once-in-a-lifetime pandemic. The sector is not without its risks, however. A few small-cap players using questionable science have sold investors on false dreams of miracle drugs that could become game-changers in their field, and in these cases, that couldn't be further from the truth.&nbsp;</p>\n<p>Avoiding bad investments is just as important as making good ones. So let's look at the dark side of investing in biotech and which companies to stay well away from.&nbsp;</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/6bccd5c36f3f76148be467937b9b6293\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"><span>Image source: Getty Images.</span></p>\n<h2>1. Cel-Sci</h2>\n<p>Sometimes, <a href=\"https://laohu8.com/S/AONE\">one</a> is dealt a bad hand in life and will need to bluff. However, it's a whole different story to double down on a bluff after <a href=\"https://laohu8.com/S/AONE.U\">one</a>'s cover is blown.&nbsp;</p>\n<p>Take the case of&nbsp;<b>Cel-Sci&nbsp;</b>(NYSEMKT:CVM), a small-cap biotech with a single late-stage immunotherapy candidate (Multikine) for treating head and neck cancer. On June 28, Cel-Sci announced that Multikine failed to achieve the primary endpoint of boosting patient survival by 10% compared to standard-of-care treatments in a decade-long phase 3 trial. As a result, the stock lost 66% of its value within four days, to $8.65.</p>\n<p>It's pretty hard to walk away from a giant bluff when there's just too much in the pot. In a conference call to investors on July 1, CEO Geert Kersten heralded the study as a \"success,\" saying that a cohort of patients who received Multikine plus surgery plus radiotherapy \"met the primary endpoint,\" and that Cel-Sci plans to file for regulatory approval. Later on in the call, chief scientific officer Taylor Eval denied all allegations the company was data-mining the study. On a side note, Kersten said he will \"not be releasing the [full] data to shareholders.\"</p>\n<p>The data that management is referring to is from a subgroup of patients in the Multikine cohort who did not receive chemotherapy in the study. This group of patients survived 14.3% longer after five years than the group who received no Multikine at all -- but that does not mean Multikine works on patients without chemotherapy. It has nothing to do with the study's primary endpoint (which includes both patients who did and did not receive chemotherapy). So the data-mining here is, in fact, pretty evident.</p>\n<p>It's also very easy to see how the drug could have a placebo effect. In clinical trials, Multikine was injected in or around the tumor. In case one was wondering, injecting just about anything into a tumor causes the cancer cells to die off -- partly due to needle damage. Moreover, patients in the 9.5-year study received Multikine for just three weeks and were not treated with the drug if their cancer relapsed. So anything (such as lifestyle choices, receiving other immunotherapies post-relapse, etc.) could have been behind the survival difference in the subgroups.</p>\n<p>Before the results came out (which took over a year), Cel-Sci bagged $31.7 million in cash by selling new stock to retail investors, resulting in heavy losses for shareholders less than three weeks after the deal closed. Overall, given the failure of its flagship candidate, the less than $50 million in assets on its books, and questionable conduct from management, this is definitely a biotech you don't want to be holding anytime soon (if not ever).&nbsp;</p>\n<h2>2. CytoDyn&nbsp;</h2>\n<p><b>CytoDyn</b> (OTC:CYDY) is a biotech known for developing leronlimab, an antibody that failed two phase 3 clinical studies for treating COVID-19. In May, the U.S. Food and Drug Administration (FDA) even released a rare statement saying that the drug did not meet the primary endpoints in these studies.&nbsp;</p>\n<p>In response, CEO Nader Pourhassan has adopted a \"catch me if you can\" type of strategy. In other words, CytoDyn simply moved outside of the FDA's jurisdiction and began commercializing the drug in countries like the Philippines.&nbsp;</p>\n<p>It's perplexing as to why the company would risk its relationship with the FDA like this. Aside from the COVID-19 indication, leronlimab is also under investigation for the treatment of HIV. In one study, leronlimab reduced viral load to negligible levels in 83% of patients with HIV.</p>\n<p>I wouldn't be surprised if the rivalry between Pourhassan and the FDA has gone down to the personal level. Last July, the FDA rejected CytoDyn's Biologic License Application (BLA) filing for leronlimab's approval for treating HIV. But the agency did not ask for another clinical trial; it just wanted additional information about the drug and a meeting with company management. CytoDyn has just begun the process to resubmit its BLA on July 1, almost a year later.</p>\n<p>At the end of the day, biotechs with sketchy science and management woes shouldn't be trading at a $1 billion market cap. Take note that CytoDyn has less than $150 million in total assets, leaving shareholders with little recourse in case of further blunders.&nbsp;</p>\n<h2>3. Northwest Biotherapeutics&nbsp;</h2>\n<p><b>Northwest Biotherapeutics</b>&nbsp;(OTC:NWBO) is a company that closely mirrors Cel-Sci in terms of both its science and stock price. Its management is also even more \"audacious\" than that of the previous companies.&nbsp;</p>\n<p>The company's flagship candidate is an immunotherapy known as DCVax-L, which is under investigation for the treatment of glioblastoma multiforme, the most deadly form of brain cancer. The phase 3 study has been going on since December 2006 (almost 15 years now). It was originally a phase 2 study, but the company \"phase-shifted\" it to 3, citing difficulty in finding patients who are comfortable taking a placebo for the deadly illness.</p>\n<p>The study had numerous red flags from the start. Northwest was supposed to conduct two interim analyses of the trial data starting in December 2013. Yes, you read that right, December of 2013. By August 2014, however, the company had released a statement claiming that \"no interim analysis of efficacy in the Phase III trial [had] been done.\" What's more, the FDA halted the DCVax-L clinical trial in August 2015 before lifting it two years later. To this day, Northwest's management has never explained the reasons behind the trial halt.</p>\n<p>The company did eventually perform the interim analyses in 2017 and 2018, but released the results unblinded. When it comes to deadly diseases with significant unmet needs, clinical trials can be stopped early if the experimental drug meets the primary endpoint for ethical reasons. That did not happen with DCVax-L on both occasions.</p>\n<p>Last October, Northwest finally announced that the trial was coming to its end and that data was to be sent for statistical analysis. It's been more than nine months since the announcement, and no news. But, again, from an ethical endpoint, if DCVax-L was working, it doesn't make sense that Northwest wouldn't release top-line data and rush the drug to approval to save lives.</p>\n<p>Shareholders should be expecting a lot of pain ahead, as the company inexplicably has a market cap of $1.27 billion -- with an unpromising candidate and less than $35 million in total assets. All of this makes Northwest's fate look eerily similar to that of Cel-Sci -- and a stock to stay away from for good.&nbsp;</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Biotechs to Avoid Like the Plague in July</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Biotechs to Avoid Like the Plague in July\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-07-07 17:05 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/07/06/3-biotechs-to-avoid-like-the-plague-in-july/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Biotech is an industry that has deeply enriched investors' pockets and helped numerous patients alike -- most recently in the form of coronavirus vaccine companies working to contain the once-in-a-...</p>\n\n<a href=\"https://www.fool.com/investing/2021/07/06/3-biotechs-to-avoid-like-the-plague-in-july/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://www.fool.com/investing/2021/07/06/3-biotechs-to-avoid-like-the-plague-in-july/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2149365051","content_text":"Biotech is an industry that has deeply enriched investors' pockets and helped numerous patients alike -- most recently in the form of coronavirus vaccine companies working to contain the once-in-a-lifetime pandemic. The sector is not without its risks, however. A few small-cap players using questionable science have sold investors on false dreams of miracle drugs that could become game-changers in their field, and in these cases, that couldn't be further from the truth. \nAvoiding bad investments is just as important as making good ones. So let's look at the dark side of investing in biotech and which companies to stay well away from. \nImage source: Getty Images.\n1. Cel-Sci\nSometimes, one is dealt a bad hand in life and will need to bluff. However, it's a whole different story to double down on a bluff after one's cover is blown. \nTake the case of Cel-Sci (NYSEMKT:CVM), a small-cap biotech with a single late-stage immunotherapy candidate (Multikine) for treating head and neck cancer. On June 28, Cel-Sci announced that Multikine failed to achieve the primary endpoint of boosting patient survival by 10% compared to standard-of-care treatments in a decade-long phase 3 trial. As a result, the stock lost 66% of its value within four days, to $8.65.\nIt's pretty hard to walk away from a giant bluff when there's just too much in the pot. In a conference call to investors on July 1, CEO Geert Kersten heralded the study as a \"success,\" saying that a cohort of patients who received Multikine plus surgery plus radiotherapy \"met the primary endpoint,\" and that Cel-Sci plans to file for regulatory approval. Later on in the call, chief scientific officer Taylor Eval denied all allegations the company was data-mining the study. On a side note, Kersten said he will \"not be releasing the [full] data to shareholders.\"\nThe data that management is referring to is from a subgroup of patients in the Multikine cohort who did not receive chemotherapy in the study. This group of patients survived 14.3% longer after five years than the group who received no Multikine at all -- but that does not mean Multikine works on patients without chemotherapy. It has nothing to do with the study's primary endpoint (which includes both patients who did and did not receive chemotherapy). So the data-mining here is, in fact, pretty evident.\nIt's also very easy to see how the drug could have a placebo effect. In clinical trials, Multikine was injected in or around the tumor. In case one was wondering, injecting just about anything into a tumor causes the cancer cells to die off -- partly due to needle damage. Moreover, patients in the 9.5-year study received Multikine for just three weeks and were not treated with the drug if their cancer relapsed. So anything (such as lifestyle choices, receiving other immunotherapies post-relapse, etc.) could have been behind the survival difference in the subgroups.\nBefore the results came out (which took over a year), Cel-Sci bagged $31.7 million in cash by selling new stock to retail investors, resulting in heavy losses for shareholders less than three weeks after the deal closed. Overall, given the failure of its flagship candidate, the less than $50 million in assets on its books, and questionable conduct from management, this is definitely a biotech you don't want to be holding anytime soon (if not ever). \n2. CytoDyn \nCytoDyn (OTC:CYDY) is a biotech known for developing leronlimab, an antibody that failed two phase 3 clinical studies for treating COVID-19. In May, the U.S. Food and Drug Administration (FDA) even released a rare statement saying that the drug did not meet the primary endpoints in these studies. \nIn response, CEO Nader Pourhassan has adopted a \"catch me if you can\" type of strategy. In other words, CytoDyn simply moved outside of the FDA's jurisdiction and began commercializing the drug in countries like the Philippines. \nIt's perplexing as to why the company would risk its relationship with the FDA like this. Aside from the COVID-19 indication, leronlimab is also under investigation for the treatment of HIV. In one study, leronlimab reduced viral load to negligible levels in 83% of patients with HIV.\nI wouldn't be surprised if the rivalry between Pourhassan and the FDA has gone down to the personal level. Last July, the FDA rejected CytoDyn's Biologic License Application (BLA) filing for leronlimab's approval for treating HIV. But the agency did not ask for another clinical trial; it just wanted additional information about the drug and a meeting with company management. CytoDyn has just begun the process to resubmit its BLA on July 1, almost a year later.\nAt the end of the day, biotechs with sketchy science and management woes shouldn't be trading at a $1 billion market cap. Take note that CytoDyn has less than $150 million in total assets, leaving shareholders with little recourse in case of further blunders. \n3. Northwest Biotherapeutics \nNorthwest Biotherapeutics (OTC:NWBO) is a company that closely mirrors Cel-Sci in terms of both its science and stock price. Its management is also even more \"audacious\" than that of the previous companies. \nThe company's flagship candidate is an immunotherapy known as DCVax-L, which is under investigation for the treatment of glioblastoma multiforme, the most deadly form of brain cancer. The phase 3 study has been going on since December 2006 (almost 15 years now). It was originally a phase 2 study, but the company \"phase-shifted\" it to 3, citing difficulty in finding patients who are comfortable taking a placebo for the deadly illness.\nThe study had numerous red flags from the start. Northwest was supposed to conduct two interim analyses of the trial data starting in December 2013. Yes, you read that right, December of 2013. By August 2014, however, the company had released a statement claiming that \"no interim analysis of efficacy in the Phase III trial [had] been done.\" What's more, the FDA halted the DCVax-L clinical trial in August 2015 before lifting it two years later. To this day, Northwest's management has never explained the reasons behind the trial halt.\nThe company did eventually perform the interim analyses in 2017 and 2018, but released the results unblinded. When it comes to deadly diseases with significant unmet needs, clinical trials can be stopped early if the experimental drug meets the primary endpoint for ethical reasons. That did not happen with DCVax-L on both occasions.\nLast October, Northwest finally announced that the trial was coming to its end and that data was to be sent for statistical analysis. It's been more than nine months since the announcement, and no news. But, again, from an ethical endpoint, if DCVax-L was working, it doesn't make sense that Northwest wouldn't release top-line data and rush the drug to approval to save lives.\nShareholders should be expecting a lot of pain ahead, as the company inexplicably has a market cap of $1.27 billion -- with an unpromising candidate and less than $35 million in total assets. All of this makes Northwest's fate look eerily similar to that of Cel-Sci -- and a stock to stay away from for good.","news_type":1,"symbols_score_info":{"CVM":0.9,"CYDY":0.9,"NWBO":0.9}},"isVote":1,"tweetType":1,"viewCount":435,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":127673749,"gmtCreate":1624848360481,"gmtModify":1631892526730,"author":{"id":"3571282373975763","authorId":"3571282373975763","name":"Asher123","avatar":"https://static.tigerbbs.com/36d4977f7e84ecc5a126c24c142136ca","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3571282373975763","authorIdStr":"3571282373975763"},"themes":[],"htmlText":"Great","listText":"Great","text":"Great","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/127673749","repostId":"1111453668","repostType":4,"isVote":1,"tweetType":1,"viewCount":333,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":124670612,"gmtCreate":1624764440136,"gmtModify":1631892526743,"author":{"id":"3571282373975763","authorId":"3571282373975763","name":"Asher123","avatar":"https://static.tigerbbs.com/36d4977f7e84ecc5a126c24c142136ca","crmLevel":5,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3571282373975763","authorIdStr":"3571282373975763"},"themes":[],"htmlText":"Wow","listText":"Wow","text":"Wow","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/124670612","repostId":"2146090006","repostType":4,"repost":{"id":"2146090006","kind":"highlight","pubTimestamp":1624755315,"share":"https://ttm.financial/m/news/2146090006?lang=&edition=full","pubTime":"2021-06-27 08:55","market":"us","language":"en","title":"5 Buffett Stocks to Buy Hand Over Fist for the Second Half of 2021","url":"https://stock-news.laohu8.com/highlight/detail?id=2146090006","media":"Motley Fool","summary":"These growth and value stocks are begging to be bought by investors.","content":"<p>When Warren Buffett buys or sells a stock, Wall Street and retail investors tend to pay very close attention. That's because the Oracle of Omaha's track record is virtually unsurpassed. Since taking the reins of <b>Berkshire Hathaway</b> (NYSE:BRK.A)(NYSE:BRK.B) in the mid-1960s, Buffett's company has averaged an annual return of 20%. This works out to an aggregate gain of greater than 2,800,000% for its Class A shares.</p>\n<p>Although Buffett isn't perfect, he and his investing team have a knack for identifying attractively valued businesses that have clear competitive advantages. As we prepare to move into the second half of 2021, the following five Buffett stocks stand out as those that should be bought hand over fist.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/1077c8372814d2b8150e933b4c608005\" tg-width=\"700\" tg-height=\"466\"><span>Berkshire Hathaway CEO Warren Buffett. Image source: The Motley Fool.</span></p>\n<h2>Amazon</h2>\n<p>Even though Buffett's investing lieutenants, Todd Combs and Ted Weschler, are the architects behind Berkshire Hathaway's stake in <b>Amazon</b> (NASDAQ:AMZN), it's arguably the Buffett stock that should be bought most aggressively ahead of the second half of the year.</p>\n<p>As most folks probably know, Amazon is an e-commerce juggernaut. Based on an April report from eMarketer, the company effectively controls $0.40 of every $1 spent online in the United States. It's also pivoted its online retail popularity into signing up more than 200 million people to its Prime program worldwide. The fees Amazon collects from Prime help it to undercut its competition on price. And it certainly doesn't hurt that Prime members tend to spend many multiples more than non-Prime shoppers during the course of the year.</p>\n<p>But it's the company's cloud infrastructure service, Amazon Web Services (AWS), that has truly budded into a star. Since the operating margins associated with cloud infrastructure are considerably higher than what Amazon nets from retail and advertising, AWS' growth is leading to a surge in operating cash flow. If investors were to continue to pay the midpoint of Amazon's operating cash flow multiple over the past decade, it could hit $10,000 a share by 2025.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/b18b49b2b35da2fc49e0a83b883d1c22\" tg-width=\"700\" tg-height=\"466\"><span>Image source: Getty Images.</span></p>\n<h2>Bristol Myers Squibb</h2>\n<p>Pharmaceutical stocks are money machines, and none looks to be more attractive on a valuation basis than <b>Bristol Myers Squibb</b> (NYSE:BMY).</p>\n<p>One reason to be excited about this drug developer is its organic growth potential. Eliquis, which was co-developed with <b>Pfizer</b>, has blossomed into the world's leading oral anticoagulant, with sales expected to surpass $10 billion in 2021. Meanwhile, dozens of additional clinical trials are underway for cancer immunotherapy Opdivo, which generated $7 billion in sales last year. This offers plenty of opportunity to expand Opdivo's label and pump up its pricing power.</p>\n<p>Another reason Bristol Myers Squibb is such an intriguing stock is its November 2019 acquisition of cancer and immunology company Celgene. Buying Celgene brought the blockbuster multiple-myeloma drug Revlimid into the fold. Revlimid has sustainably grown its annual sales by a double-digit percentage for more than a decade, with label expansion, longer duration of use, and pricing power all playing a role. This key treatment, which topped $12 billion in sales last year, is protected from a full onslaught of generic competition until early 2026. That means Bristol Myers will be rolling in the dough for another five years, at minimum.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/1b152e369d7c967dcbc926192ee888c1\" tg-width=\"700\" tg-height=\"531\"><span>Image source: Getty Images.</span></p>\n<h2>Mastercard</h2>\n<p>Everyone seems to be looking for the smartest recovery play from the pandemic. Payment processor <b>Mastercard</b> (NYSE:MA) might well be the safest way to take advantage of a steady uptick in consumer and enterprise spending.</p>\n<p>Mastercard isn't a cheap stock by any means -- at 36 times Wall Street's forward-year earnings consensus -- but it benefits from a simple numbers game. While economic contractions and recessions are inevitable, these periods of turbulence tend to be short-lived. By comparison, economic expansions often last many years. Buying into Mastercard allows investors to take full advantage of these long periods of economic expansion and robust spending. Plus, it doesn't hurt that Mastercard has the second-highest share of credit-card network purchase volume in the U.S., the leading market for consumption.</p>\n<p>Investors can also sleep easy with the understanding that Mastercard strictly sticks to payment facilitation. Even though some of its peers also lend, and are therefore able to generate interest income and fees during bull markets, Mastercard has avoided becoming a lender. It's something you'll truly appreciate when a recession strikes. Whereas most financial stocks will be forced to set aside capital to cover credit or loan delinquencies, Mastercard won't have to. This is a big reason it bounces back from recessions quicker than most financial stocks.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/e4e1a1fe028efa4c966b66ef2cd466f5\" tg-width=\"700\" tg-height=\"466\"><span>Image source: Getty Images.</span></p>\n<h2>Teva Pharmaceutical Industries</h2>\n<p>If you have an appetite for turnaround plays, brand-name and generic-drug developer <b>Teva Pharmaceutical Industries</b> (NYSE:TEVA) is the stock to buy hand over fist for the second half of 2021. Like Amazon, it's a stock that was added to Berkshire Hathaway's portfolio by either Combs or Weschler and not Buffett.</p>\n<p>While there's no denying that Teva has its fair share of hurdles to overcome, the company's turnaround-focused CEO, Kare Schultz, has been a blessing. Since taking the helm less than four years ago, Schultz has helped shave off more than $10 billion in net debt, and he's overseen the reduction of roughly $3 billion in annual operating expenses. There's more work to do to improve Teva's balance sheet, but the company is very clearly on much firmer ground than it was back in 2016-2017.</p>\n<p>Schultz also has the potential to play peacemaker for a number of outstanding lawsuits targeting Teva's role in the opioid crisis. If this litigation can be resolved with minimal cash outlay, Teva's valuation could soar. At just 4 times the company's projected earnings in 2021, Teva is about as cheap as a healthcare stock can get.</p>\n<p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/44a30c4dfd6886a29e22d3c6558c3e56\" tg-width=\"700\" tg-height=\"466\"><span>Image source: Getty Images.</span></p>\n<h2>Bank of America</h2>\n<p>Lastly, bank stock <b>Bank of America</b> (NYSE:BAC) has the look of a company that can be confidently bought hand over fist for the second half of 2021.</p>\n<p>For much of the past decade, the Federal Reserve has kept interest rates at or near historic lows. That's meant less in the way of interest income for banks. But the latest update from the nation's central bank suggests that interest rates could begin creeping up in 2023, a year earlier than previously forecast. Bank of America is the most interest-sensitive money-center bank. According to its first-quarter investor presentation, BofA would generate $8.3 billion in net interest income on a 100-basis-point shift in the interest rate yield curve. Translation: Bank of America's profits should rocket higher beginning in 2023-2024.</p>\n<p>At the same time, BofA has done an outstanding job of controlling its costs and improving its operating efficiency. Investments in digitization have resulted in higher mobile app and digital banking use, which is allowing the company to consolidate some of its branches. Even with its shares at a 13-year high, Bank of America has plenty left in the tank.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>5 Buffett Stocks to Buy Hand Over Fist for the Second Half of 2021</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n5 Buffett Stocks to Buy Hand Over Fist for the Second Half of 2021\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-27 08:55 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/06/26/buffett-stocks-buy-hand-over-fist-second-half-2021/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>When Warren Buffett buys or sells a stock, Wall Street and retail investors tend to pay very close attention. That's because the Oracle of Omaha's track record is virtually unsurpassed. Since taking ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/06/26/buffett-stocks-buy-hand-over-fist-second-half-2021/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BMY":"施贵宝","BRK.A":"伯克希尔","AMZN":"亚马逊","MA":"万事达","BRK.B":"伯克希尔B","BAC":"美国银行","TEVA":"梯瓦制药"},"source_url":"https://www.fool.com/investing/2021/06/26/buffett-stocks-buy-hand-over-fist-second-half-2021/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2146090006","content_text":"When Warren Buffett buys or sells a stock, Wall Street and retail investors tend to pay very close attention. That's because the Oracle of Omaha's track record is virtually unsurpassed. Since taking the reins of Berkshire Hathaway (NYSE:BRK.A)(NYSE:BRK.B) in the mid-1960s, Buffett's company has averaged an annual return of 20%. This works out to an aggregate gain of greater than 2,800,000% for its Class A shares.\nAlthough Buffett isn't perfect, he and his investing team have a knack for identifying attractively valued businesses that have clear competitive advantages. As we prepare to move into the second half of 2021, the following five Buffett stocks stand out as those that should be bought hand over fist.\nBerkshire Hathaway CEO Warren Buffett. Image source: The Motley Fool.\nAmazon\nEven though Buffett's investing lieutenants, Todd Combs and Ted Weschler, are the architects behind Berkshire Hathaway's stake in Amazon (NASDAQ:AMZN), it's arguably the Buffett stock that should be bought most aggressively ahead of the second half of the year.\nAs most folks probably know, Amazon is an e-commerce juggernaut. Based on an April report from eMarketer, the company effectively controls $0.40 of every $1 spent online in the United States. It's also pivoted its online retail popularity into signing up more than 200 million people to its Prime program worldwide. The fees Amazon collects from Prime help it to undercut its competition on price. And it certainly doesn't hurt that Prime members tend to spend many multiples more than non-Prime shoppers during the course of the year.\nBut it's the company's cloud infrastructure service, Amazon Web Services (AWS), that has truly budded into a star. Since the operating margins associated with cloud infrastructure are considerably higher than what Amazon nets from retail and advertising, AWS' growth is leading to a surge in operating cash flow. If investors were to continue to pay the midpoint of Amazon's operating cash flow multiple over the past decade, it could hit $10,000 a share by 2025.\nImage source: Getty Images.\nBristol Myers Squibb\nPharmaceutical stocks are money machines, and none looks to be more attractive on a valuation basis than Bristol Myers Squibb (NYSE:BMY).\nOne reason to be excited about this drug developer is its organic growth potential. Eliquis, which was co-developed with Pfizer, has blossomed into the world's leading oral anticoagulant, with sales expected to surpass $10 billion in 2021. Meanwhile, dozens of additional clinical trials are underway for cancer immunotherapy Opdivo, which generated $7 billion in sales last year. This offers plenty of opportunity to expand Opdivo's label and pump up its pricing power.\nAnother reason Bristol Myers Squibb is such an intriguing stock is its November 2019 acquisition of cancer and immunology company Celgene. Buying Celgene brought the blockbuster multiple-myeloma drug Revlimid into the fold. Revlimid has sustainably grown its annual sales by a double-digit percentage for more than a decade, with label expansion, longer duration of use, and pricing power all playing a role. This key treatment, which topped $12 billion in sales last year, is protected from a full onslaught of generic competition until early 2026. That means Bristol Myers will be rolling in the dough for another five years, at minimum.\nImage source: Getty Images.\nMastercard\nEveryone seems to be looking for the smartest recovery play from the pandemic. Payment processor Mastercard (NYSE:MA) might well be the safest way to take advantage of a steady uptick in consumer and enterprise spending.\nMastercard isn't a cheap stock by any means -- at 36 times Wall Street's forward-year earnings consensus -- but it benefits from a simple numbers game. While economic contractions and recessions are inevitable, these periods of turbulence tend to be short-lived. By comparison, economic expansions often last many years. Buying into Mastercard allows investors to take full advantage of these long periods of economic expansion and robust spending. Plus, it doesn't hurt that Mastercard has the second-highest share of credit-card network purchase volume in the U.S., the leading market for consumption.\nInvestors can also sleep easy with the understanding that Mastercard strictly sticks to payment facilitation. Even though some of its peers also lend, and are therefore able to generate interest income and fees during bull markets, Mastercard has avoided becoming a lender. It's something you'll truly appreciate when a recession strikes. Whereas most financial stocks will be forced to set aside capital to cover credit or loan delinquencies, Mastercard won't have to. This is a big reason it bounces back from recessions quicker than most financial stocks.\nImage source: Getty Images.\nTeva Pharmaceutical Industries\nIf you have an appetite for turnaround plays, brand-name and generic-drug developer Teva Pharmaceutical Industries (NYSE:TEVA) is the stock to buy hand over fist for the second half of 2021. Like Amazon, it's a stock that was added to Berkshire Hathaway's portfolio by either Combs or Weschler and not Buffett.\nWhile there's no denying that Teva has its fair share of hurdles to overcome, the company's turnaround-focused CEO, Kare Schultz, has been a blessing. Since taking the helm less than four years ago, Schultz has helped shave off more than $10 billion in net debt, and he's overseen the reduction of roughly $3 billion in annual operating expenses. There's more work to do to improve Teva's balance sheet, but the company is very clearly on much firmer ground than it was back in 2016-2017.\nSchultz also has the potential to play peacemaker for a number of outstanding lawsuits targeting Teva's role in the opioid crisis. If this litigation can be resolved with minimal cash outlay, Teva's valuation could soar. At just 4 times the company's projected earnings in 2021, Teva is about as cheap as a healthcare stock can get.\nImage source: Getty Images.\nBank of America\nLastly, bank stock Bank of America (NYSE:BAC) has the look of a company that can be confidently bought hand over fist for the second half of 2021.\nFor much of the past decade, the Federal Reserve has kept interest rates at or near historic lows. That's meant less in the way of interest income for banks. But the latest update from the nation's central bank suggests that interest rates could begin creeping up in 2023, a year earlier than previously forecast. Bank of America is the most interest-sensitive money-center bank. According to its first-quarter investor presentation, BofA would generate $8.3 billion in net interest income on a 100-basis-point shift in the interest rate yield curve. Translation: Bank of America's profits should rocket higher beginning in 2023-2024.\nAt the same time, BofA has done an outstanding job of controlling its costs and improving its operating efficiency. Investments in digitization have resulted in higher mobile app and digital banking use, which is allowing the company to consolidate some of its branches. Even with its shares at a 13-year high, Bank of America has plenty left in the tank.","news_type":1,"symbols_score_info":{"AMZN":0.9,"BAC":0.9,"BMY":0.9,"BRK.A":0.9,"BRK.B":0.9,"MA":0.9,"TEVA":0.9}},"isVote":1,"tweetType":1,"viewCount":314,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"defaultTab":"posts","isTTM":false}